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Alpha 1-Antitrypsin (AAT) deficiency is a human genetic disease resulting in the production of mutant 
AAT, a hepatocyte produced serine protease inhibitor that functions to prevent alveolar epithelial 
damage by inhibiting neutrophil elastase. Patients with AAT deficiency have increased lung disease, due 
to decreased proteolytic protection, as well as sporadic severe liver disease secondary to accumulation 
of mutant AAT, especially a common mutant form termed PiZ, within hepatocytes. We previously 
showed, in a PiZ mutant mouse model, simultaneous knock-down of mutant PiZ-AAT and augmentation 
of wild-type AAT production through intravenous delivery of a recombinant adeno-associated viral 
(rAAV) vector encoding both a miRNA targeting PiZ-AAT and a miRNA-resistant wild-type AAT gene.  
 
In this study we tested the hypothesis that rAAV2/9 vector administered intra-nasally or intra-tracheally 
can deliver a gene of interest to both the airways and liver.  
 
Initially C57Bl/6 mice were administered intra-nasally 1011 genome copies (GC) of rAAV2/9 vector 
expressing a firefly luciferase, which resulted in increased luminescence in the nasal passages, liver, and 
lung 21 days post delivery. Next, 1012 GC of rAAV2/9 vector expressing GFP and miRNAs targeting PiZ-
AAT were delivered via oro-tracheal intubation to PiZ mice. This resulted in decreased serum AAT levels 
in the PiZ mice and GFP expression in both the liver and lungs. Finally, 1012 GC of rAAV2/9 vector 
encoding miRNA resistant wild-type AAT and miRNAs targeting PiZ-AAT were delivered via oro-tracheal 
intubation. This resulted in both systemic and local (liver and lung) elevations in wild-type AAT as well as 
decreased PiZ-AAT levels. 
 
In conclusion, tracheal delivery of rAAV2/9 resulted in expression of AAT in the liver and lung of treated 
animals, with sufficient targeting of the liver to mediate knock-down of mutant AAT to a similar degree 
as intravenous delivery, representing a potential non-invasive delivery route for gene therapy in AAT 
deficient patients.  
